SLC27A2 and neoplasm: Additionally, lipofermata inhibition of FATP2 in MDSCs was also found to decrease lipid accumulation-induced ROS, block immunosuppressive activity, and consequently enhance anti-PD-L1 tumor immunotherapy via the activation of T cells in melanoma and lung cancer (126).